16 September 2026 editorial review · Item
Dimethyl fumarate for beta-cell preservation: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Both dimethyl-fumarate T1D trials recruit with C-peptide endpoints but no posted efficacy. MS approval and safety experience do not establish benefit-risk in T1D; no outcome upgrade.
- Registry NCT07258394: RECRUITING; updated 2026-03-05; enrollment 90 (ESTIMATED); primary completion 2028-12-31 (ESTIMATED); results not posted in retrieved record.
- Registry NCT07548996: RECRUITING; updated 2026-07-21; enrollment 96 (ESTIMATED); primary completion 2028-12-31 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: 204063s031lbl.pdf.